RGEN - repligen.com Operating profit before depreciation charges
Repligen Corporation provides the biopharmaceutical industry with critical filters, creating a steady cash flow through consumables. The absolute EBITDA trend visualizes the actual business efficiency, where the value 166.03 captures this metric. Cost optimization via outsourcing standard components while maintaining patent control minimizes risks. However, excess client inventories and reductions in R&D budgets could slow revenue growth.
Repligen (RGEN) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- market capitalization statistics:
- company book value details:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Repligen Corporation|RGEN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Repligen Corp|RGEN - Company Debts|Debts to Book Value Repligen|RGEN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Repligen|Critical Liquidity Ratio repligen.com
- earnings and market multiples details:
RGEN - Company Net Income|Expected Net Profit Repligen Corporation|RGEN - Price to Earnings Ratio|Future Price to Earnings Multiple repligen.com|RGEN - PEG Multiple|EV/EBITDA Multiple Repligen|RGEN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Repligen|RGEN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months repligen.com|RGEN - Earnings per share growth in current year|Expected net earnings per share growth next year Repligen Corporation
Analysis of all company metrics:Repligen Corporation
This metric measures net cash flow from operating activities, excluding the impact of depreciation and taxes to assess the business's actual ability to generate cash. The EBITDA dynamics of Repligen Corporation (RGEN) demonstrate how its gold-standard status in biopharmaceuticals converts into capital, confirming the financial stability of Repligen Corporation (RGEN) while scaling the supply of high-precision equipment to the world's largest laboratories.
Competitors of Repligen Corporation (RGEN)
Operating income before deduction of amortization Tempus (TEM)|Qiagen N.V. - Operating profit EBITDA|Operating profit before depreciation charges ionispharma.com (IONS)|RNA: Operating profit EBITDA|Profit before interest, taxes and amortization CRISPR Therapeutics Inc (CRSP)|Profit before payment of interest, taxes and amortization Sema4|Operating profit before amortization RARE (Ultragenyx Corp)|Operating profit before deduction of amortization BEAM (Beam Therapeutics Inc.)|SRPT (sarepta.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TWST (Twist Bioscience, Inc.)|TXG - Operating profit before deduction of amortization|NTLA - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Stoke Corp|BioLife Solutions, Inc. (BLFS) - Profit before payment of interest, taxes and amortization|wavelifesciences.com - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Maze Therapeutics|Sionna Therapeutics, Inc. - Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Prime Medicine Corp (PRME)|TSHA - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization uniQure N.V. QURE|Income before deduction of interest, taxes and amortization MGTX|REGENXBIO - Operating profit EBITDA|SLDB - Operating profit EBITDA|OCGN (Ocugen Corp) - Operating profit before deduction of amortization|PACB: Company profit before taxes, interest and amortization|BNTC (Benitec Biopharma Inc.) - Operating profit EBITDA|designtx.com (DSGN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Rocket Pharmaceuticals, Inc. (RCKT)|FDMT - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|EDIT - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization SLN (silence-therapeutics.com)|PRQR: Operating profit EBITDA|Operating profit before depreciation charges Codexis CDXS|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Operating profit EBITDA GBIO (Generation Bio)|BOLD: Operating profit before amortization|XCUR - Profit before payment of interest, taxes and amortization|IMNN (Imunon, Inc.) - Operating profit before amortization|PHIO: Operating profit EBITDA|Mustang Bio (MBIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|BNGO: Income before deduction of interest, taxes and amortization|Operating profit EBITDA APDN|BLUE - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|OMGA (omegatherapeutics.com) - Profit before deduction of interest, taxes, depreciation and amortization|OMIC - Profit before payment of interest, taxes and amortization|RGLS: Profit before payment of interest, taxes and amortization|SYRS: Operating profit EBITDA|TBIO - Operating income before deduction of amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|UBX - Operating profit before depreciation charges
